+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years +
All Genders
ID06815029

Evaluating Safety of Intracranial TGFR2KOIL13R2 CAR T-Cells for Recurrent or Progressive High-Grade Glioma Including Glioblastoma and IDH-Mutant Astrocytoma

Led by City of Hope Medical Center · Updated on 2026-10-22

27

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety, side effects, and best dose of TGFR2KOIL13R2 chimeric antigen receptor CAR T-cells given directly into the brain intracranial to treat patients with recurrent or progressive glioblastoma or grade 3 or 4 IDH-mutant astrocytoma. This phase I trial studies how these genetically modified immune cells, made from a patients own T cells, can target tumor cells and potentially affect tumor growth or progression. Participants undergo leukapheresis to collect T cells and may have standard surgical tumor removal with or without placement of a Rickham catheter. Starting on day 0, patients receive weekly intracranial infusions of the autologous CAR T cells over about 5 minutes, repeated for up to 4 weekly cycles 28 days unless disease worsens or unacceptable side effects occur. Additional cycles may be given if criteria are met. The study also includes imaging with MRI and FDG-PET scans and sample collection of cerebrospinal fluid and blood to monitor treatment effects. Throughout the study, participants have scheduled assessments including blood tests, scans, and possibly echocardiography at screening. Follow-up visits occur on day 30, and at 3, 6, 9, and 12 months, then yearly for up to 15 years to monitor safety, treatment response, survival, and immune cell behavior. Researchers also analyze tumor and immune environment changes and track side effects like cytokine release syndrome during and after treatment.

CONDITIONS

Brief Title

Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progressive Glioblastoma or Grade 3 or 4 IDH-Mutant Astrocytoma

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here